Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04463004

Recruitment Status : Active, not recruiting

First Posted : July 9, 2020

Last Update Posted : February 17, 2021

Sponsor:

Collaborator:

Kiniksa Pharmaceuticals, Ltd.

Information provided by (Responsible Party):

Virginia Commonwealth University

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	August 2021
Estimated Study Completion Date :	August 2021

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Cremer PC, Abbate A, Hudock K, McWilliams C, Mehta J, Chang SY, Sheng CC, Van Tassell B, Bonaventura A, Vecchié A, Carey B, Wang Q, Wolski KE, Rajendram P, Duggal A, Wang TS, Paolini JF, Trapnell BC; MASH-COVID study group. Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Rheumatol. 2021 Mar 17. doi: 10.1016/S2665-9913(21)00070-9. [Epub ahead of print]

To Top